CLINICAL USE


Antiprotozoal agent:Malaria Toxoplasmosis

DOSE IN NORMAL RENAL FUNCTION

Malaria: used in dual drug combinations Malaria prophylaxis: 25 mg weekly Toxoplasmosis: 100–200 mg daily for 2–3 days then 25–100 mg daily for 2–6 weeks (in combination with sulfadiazine)

PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :248.7
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :80–90
  • %Excreted unchanged in urine &nbsp &nbsp : 15–30
  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp :2
  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :35–175/Unchanged

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in normal renal function
  • HDF/high flux &nbsp :Unknown dialysability. Dose as in normal renal function
  • CAV/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsIncreased antifolate effect with sulphonamides, trimethoprim and methotrexate
  • Anti-epileptics: anticonvulsant effect antagonised; increased antifolate effect with phenytoin
  • Antimalarials: avoid concomitant use with artemether/lumefantrine; increased antifolate effect with proguanil

    ADMINISTRATION

    Reconstition

    Route

    Oral

    Rate of Administration

    Comments

    OTHER INFORMATION

    Pyrimethamine should always be administered with a folate supplement to reduce the risk of bone marrow depression.